Get the Stockscreener App
8.28
0.60%
-0.05
After Hours:
8.27
-0.010
-0.12%
Jade Biosciences Inc stock is traded at $8.28, with a volume of 74,381.
It is down -0.60% in the last 24 hours and down -21.22% over the past month.
Jade Biosciences Inc is focused on developing therapies to address critical unmet needs in autoimmune diseases. Its asset, JADE-001, will target the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for immunoglobulin A (IgA) nephropathy, with Investigational New Drug Application-enabling studies underway and initiation of a first-in-human trial. Jade's pipeline also includes two undisclosed optimized antibody discovery programs, JADE-002 and JADE-003, currently in preclinical development. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount.
See More
Previous Close:
$8.33
Open:
$8.46
24h Volume:
74,381
Relative Volume:
0.21
Market Cap:
$268.53M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-12.57%
1M Performance:
-21.22%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$7.90
$8.46
1-Week Range:
$7.90
$9.5693
52-Week Range:
$6.565
$13.47
Jade Biosciences Inc Stock (JBIO) Company Profile
Name
Jade Biosciences Inc
Sector
Industry
Phone
617-443-2400
Address
930 WINTER STREET, WALTHAM
Compare JBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JBIO
Jade Biosciences Inc
|
8.28 | 268.53M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Jade Biosciences Inc Stock (JBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-14-25 | Initiated | Jefferies | Buy |
| Jun-16-25 | Upgrade | Guggenheim | Neutral → Buy |
| May-07-25 | Initiated | Wedbush | Outperform |
| May-05-25 | Initiated | Stifel | Buy |
| May-02-25 | Initiated | TD Cowen | Buy |
| Jun-18-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Jun-18-24 | Downgrade | TD Cowen | Buy → Hold |
| Jun-18-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jun-17-24 | Downgrade | BTIG Research | Buy → Neutral |
| Jun-17-24 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-17-24 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-25-24 | Resumed | Jefferies | Buy |
| Dec-08-23 | Initiated | Wells Fargo | Equal Weight |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Dec-06-22 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-19-22 | Resumed | Wedbush | Outperform |
| Aug-16-22 | Downgrade | BTIG Research | Buy → Neutral |
| Feb-11-22 | Initiated | BTIG Research | Buy |
| Jul-26-21 | Initiated | Cowen | Outperform |
| Jul-26-21 | Initiated | Evercore ISI | Outperform |
| Jul-26-21 | Initiated | Jefferies | Buy |
| Jul-26-21 | Initiated | Wedbush | Outperform |
View All
Jade Biosciences Inc Stock (JBIO) Latest News
What catalysts could drive Jade Biosciences Inc. stock higher in 2025Invest smarter with cutting-edge analytics - jammulinksnews.com
Is Jade Biosciences Inc. stock overvalued or undervaluedInvest confidently with professional guidance - jammulinksnews.com
What is the risk reward ratio of investing in Jade Biosciences Inc. stockInvest confidently with professional advice - jammulinksnews.com
Is Jade Biosciences Inc. a growth stock or a value stockReal-time trading signals for maximum returns - jammulinksnews.com
What are the latest earnings results for Jade Biosciences Inc.Accelerated wealth building - jammulinksnews.com
What institutional investors are buying Jade Biosciences Inc. stockAccess exclusive market insights for free - jammulinksnews.com
How Resilient Is Jade Biosciences Inc. Stock During Economic DownturnsHigh Return Investment Tips - Newser
Jade Biosciences Inc. Company’s Quarterly Earnings Growth: What the Numbers SayFree Access to Investment Community - Newser
Is Jade Biosciences Inc. a Top Dividend Stock to Watch in 2025Low Drawdown Trade Signals - Newser
What makes Jade Biosciences Inc. stock price move sharplyRapid Gain Targets - Metal.it
How Jade Biosciences Inc. stock performs during market volatilityFree Risk Assessment Services - Newser
Jade Biosciences Inc. Stock Analysis and ForecastRecord-setting profit potential - PrintWeekIndia
How high can Jade Biosciences Inc. stock price go in 2025Powerful growth strategies - jammulinksnews.com
What analysts say about Jade Biosciences Inc. stockLightning-fast capital gains - PrintWeekIndia
Is Jade Biosciences Inc. a good long term investmentExplosive portfolio gains - PrintWeekIndia
What drives Jade Biosciences Inc. stock priceUnstoppable profit momentum - PrintWeekIndia
Why Jade Biosciences Inc. stock is on top investor watchlistsFree Predictions - jammulinksnews.com
IGM Biosciences Inc. Stock Analysis and ForecastLightning-fast growth - Autocar Professional
Jade Biosciences appoints Brad Dahms as CFO - MSN
Why Jade Biosciences Inc. stock attracts strong analyst attentionReal Time Stock Signal - Newser
Jade Biosciences Inc Stock (JBIO) Financials Data
There is no financial data for Jade Biosciences Inc (JBIO). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.97%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):